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Most invasive bacterial infections are caused by species that more commonly 
colonize the human host with minimal symptoms. Although phenotypic or 
genetic correlates underlying a bacterium’s shift to enhanced virulence have 
been studied, the in vivo selection pressure governing such shifts are poorly 
understood. The globally disseminated M1T1 clone of group A Streptococcus 
(GAS) is linked with rare but life-threatening syndromes of necrotizing fasciitis 
and toxic shock syndrome1. Mutations in the GAS control of virulence 
regulatory sensor kinase (covRS) operon are associated with severe invasive 
disease, abolishing expression of a broad spectrum cysteine protease (SpeB)2,3 
and allowing the recruitment and activation of host plasminogen on the bacterial 
surface4. Here we describe how bacteriophage-encoded GAS DNase (Sda1), 
which facilitates the pathogen’s escape from neutrophil extracellular traps 
(NETs)5,6, serves as a selective force for covRS mutation. The results provide a 
paradigm whereby natural selection exerted by the innate immune system 
generate hypervirulent bacterial variants with increased risk of systemic 
dissemination. 
 
GAS is estimated to cause ~700 million cases of self-limited throat or skin infection 
each year worldwide7. Invasive GAS disease occurs in approximately 1/1,000 cases, 
with associated mortality of 25%7. Epidemic invasive disease is associated with the 
emergence of the globally disseminated GAS M1T1 clone1,8, which is distinguished 
from related strains by acquisition of prophages encoding virulence determinants such 
as superantigen SpeA and DNase Sda19,10. In the M1T1 GAS clone, the transition 
from local to systemic infection can be linked to mutations in the two-component 
covRS regulator. The effect of these mutations is a distinct shift in the transcriptional 
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profile of invasive GAS isolates compared to mucosal (throat) isolates3. The covRS 
mutation and changes in gene expression are recapitulated upon subcutaneous 
challenge of mice and analysis of GAS disseminating to the spleen in comparison 
with those in the original inocolum3. Prominent changes in the transcriptional profile 
of invasive GAS isolates include a strong up-regulation of the DNase gene sda1, and 
a marked decrease in expression of the gene encoding the cysteine protease SpeB3.  
Sda1 is a virulence factor that protects GAS against neutrophil killing by degrading 
the DNA framework of NETs5,6. Abolishment of SpeB expression allows 
accumulation and activation of the broad spectrum host protease plasmin on the GAS 
bacterial surface4. A clinical correlation of GAS invasive disease severity and 
diminished SpeB expression has been established2.  
 
To elucidate the selection pressure for the rapid loss of SpeB expression in vivo, we 
have compared the human M1T1 GAS isolate 5448 and its isogenic animal passaged 
SpeB-negative variant 5448AP11. DNA sequence analysis shows 5448AP contains a 
single adenine base insertion at position 877 of the covS gene (Fig. 1a) and lacks 
SpeB production (Fig. 1b). Whilst equivalent to wild-type (WT) 5448 in expression 
of plasminogen receptors α-enolase12 and GAPDH13, 5448AP exhibits higher levels 
of the fibrinogen-binding M1 protein14,15 and streptokinase (Fig. 1c). Although 
washed 5448 and 5448AP cells bind identical levels of human plasminogen (Fig. 1d), 
5448AP accumulates significantly higher levels of surface plasmin activity following 
growth in human plasma (P < 0.05; Fig. 1e). The observed phenotypes of 5448AP 
parallel those seen upon allelic replacement of the speB gene in the parent strain 
(mutant 5448ΔspeB4), indicating that surface plasmin acquisition by 5448AP reflects 
the loss of SpeB. Additionally, other gene expression changes, such as the increase in 
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streptokinase expression associated with covRS mutation3, may also contribute to 
surface plasmin acquisition by 5448AP (Supplementary Fig. 1). Compared to WT, 
the 5448AP strain was found to be hypervirulent in a humanized plasminogen mouse 
subcutaneous infection model (P < 0.05; Fig. 1f and Supplementary Fig. 2). Isogenic 
mutagenesis of 5448AP was undertaken to construct a streptokinase-deficient strain 
(5448APΔska), which showed reduced virulence in comparison to 5448AP (P < 0.05; 
Fig. 1f). This observation is consistent with the reduced virulence of ska-deficient 
GAS previously reported16. Enumeration of bacterial counts in the site of infection, 
blood, spleen and liver of humanized plasminogen mice, suggest that the enhanced 
virulence of strain 5448AP is as a result of a widespread systemic infection following 
breakout from the site of local infection, immediately prior to the death of the mice 
(Fig. 1g). These humanized animal model data reflect observations made in the 
clinical setting for GAS M1T1 strains, where mutations in covRS correlate with 
human invasive disease severity2,3. 
 
Next, infection chambers were implanted subcutaneously in mice and inoculated with 
either GAS 5448 or 5448AP. After 24 h, bacteria were recovered and analyzed for 
SpeB and Sda1 expression. Quantitative real-time PCR analysis reveals speB 
expression is down-regulated over 10,000× in 5448AP, when compared to WT 5448 
(Fig. 2a). In contrast, an over 5× up-regulation of sda1 gene expression was observed 
by 24 h in 5448 following in vivo growth, which matched the increased DNase 
expression levels seen in vivo for 5448AP (Fig. 2b and Supplementary Fig. 3a). 
DNA degradation by 5448AP was increased compared to the GAS 5448 parent strain 
(Fig. 2c and Supplementary Fig. 3b), consistent with both the up-regulation of sda1 
expression and the known ability of SpeB to degrade Sda111. Compared to the 5448 
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parent strain, the enhanced DNase activity of 5448AP was associated with clearance 
of NETs (Fig. 2d and Supplementary Fig. 4a) and increased resistance to neutrophil 
killing (Fig. 2e). Neither streptokinase nor M1 protein contribute to NET clearance 
(Supplementary Fig. 4b). 
 
Neutrophils and NET-mediated extracellular killing play a pivotal role in antibacterial 
clearance at the initial site of infection5,17. We hypothesized that acquisition of the 
potent bacteriophage-encoded DNase Sda1 by the M1T1 clone provides the selective 
force for loss of SpeB expression in vivo, since the cysteine protease is capable of 
degrading this important neutrophil survival factor. To examine this possibility, we 
subcutaneously challenged C57BL/J6 mice separately with 5448 and the isogenic 
5448Δsda1 mutant, predicting that absence of Sda1 would reduce the selective 
advantage for mutation to a SpeB-negative phenotype. Loss of SpeB expression in 
vivo during subcutaneous mouse infection was abrogated in the isogenic 5448Δsda1 
mutant compared to WT 5448 (Fig. 2f; 1/500 SpeB-negative 5448Δsda1 colony 
versus 76/500 SpeB-negative 5448 colonies; P < 0.05). DNA sequence analysis of 10 
selected SpeB-negative 5448 colonies suggests that mutations in covRS have resulted 
in loss of SpeB expression (Supplementary Table 1), as previously reported3. We 
used reverse complementation to replace the mutated chromosomal locus in 
5448Δsda1 with the WT allele to construct 5448RCsda1+. This complemented mutant 
regained the capacity to switch to the SpeB-negative phenotype (Fig. 2f; 45/500 
SpeB-negative 5448RCsda1+ colonies; P = 0.39). The isogenic mutant 5448Δsmez, 
derived in a manner identical to 5448Δsda1, was found to retain the capacity to phase-
switch similar to the WT strain 5448 (Fig. 2f; 33/500 SpeB-negative 5448Δsmez 
colonies; P = 0.11). These observations suggest that the phase-switching phenotype is 
 6
due to allelic replacement of the sda1 gene and not due to the methodology used to 
construct an isogenic GAS mutant in strain 5448. The M1 serotype GAS strain SF370 
is known not to encode Sda19,10. SF370 was found to have minimal capacity to switch 
to the SpeB-negative phenotype compared to 5448 (Fig. 2f; 2/500 SpeB-negative 
SF370 colonies; P < 0.05) consistent with the absence of Sda1 and thus lack of 
selective advantage for mutation to the SpeB-negative phenotype.  
 
The globally disseminated Streptococcus pyogenes M1T1 clone emerged in the mid-
1980s as a major cause of severe GAS invasive disease. Recent genome-scale 
analyses have found that in comparison to other M1 strains, the M1T1 clone has 
acquired two lysogenised bacteriophage genomes encoding Sda1 and SpeA, 
respectively9,10. While the introduction of SpeA into the GAS population increases the 
propensity to cause streptococcal toxic shock, this study has shown that positive 
selection pressure in vivo is placed upon the bacteriophage-encoded virulence 
determinant Sda1. Loss of SpeB spares Sda1 from degradation11 and improves GAS 
resistance against neutrophil clearance. In vivo, the phase-shift in SpeB expression is 
abrogated by isogenic mutagenesis of sda1. The genetic basis for loss of SpeB 
expression has been previously described3. Loss of SpeB has also been shown to 
result in increased invasive propensity of M1T1 by the accumulation of surface-bound 
plasmin activity4. Therefore, we hypothesize that the bacteriophage-mediated 
acquisition of the sda1 gene by the ancestral M1T1 has provided evolutionary 
selection pressure for increased neutrophil resistance via SpeB loss, which results in a 
hyperinvasive phenotype and can lead to severe invasive disease progression (Fig. 3). 
The evolution of bacterial pathogens principally occurs either through deletion events 
or horizontal gene transfer and acquisition18, which is exemplified by the 
 7
bacteriophage-mediated acquisition of the sda1 gene by M1T1. These data provide a 
paradigm for bacteriophage-mediated acquisition of virulence determinants and 
development of severe disease by otherwise benign human pathogens. 
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Figure legends: 
 
Fig. 1. Molecular and phenotypic analyses of GAS strains 5448 and 5448AP. (a) 
DNA sequence comparison of GAS strains 5448 and 5448AP confirms the presence 
of a 1 base adenine addition at the 3’ end of covS (nt position 877) encoded by 
5448AP (unfilled arrowhead). Primers used for DNA sequence analysis are indicated 
by filled arrowheads (p1 to p12). This insertion mutation results in the truncation of 
the CovS open reading frame at amino acid 300 from the CovS methionine start 
codon. Putative conserved CovS domains are indicated in lower panel: HAMP: 
Histidine kinases/adenylyl cyclases/methyl-binding proteins/phosphatases; HisKA, 
Histidine kinase domain (phosphoacceptor); HATPase: Histidine kinase-like ATPase. 
Scales, in base pairs (bp; upper panel bar) and amino acids (aa; lower panel bar), are 
indicated. (b) In comparison to GAS strain 5448, secreted SpeB protease activity is 
abrogated in 5448AP (n = 3; mean ± SD). Asterisk indicates statistically significant 
difference from 5448, where P < 0.05. (c) Western blot analysis of cell wall extracts 
indicates that equivalent amounts of α-enolase (unfilled arrowhead) and GAPDH 
(unfilled arrowhead) are produced by strains 5448 and 5448AP, whereas higher 
amount of M1 protein (unfilled arrowhead) is produced in cell wall extracts and 
streptokinase (unfilled arrowhead) is secreted into culture supernatants by strain 
5448AP, in comparison to 5448. Molecular mass markers (MWT) are given in kilo-
Daltons (kDa). (d) Washed 5448 and 5448AP cells bind equivalent amounts of human 
plasminogen (n = 3; mean ± SD). (e) Following overnight growth at 37 oC in human 
plasma, 5448AP accumulates significantly higher levels of surface plasmin activity (n 
= 3; mean ± SD). Asterisk indicates statistically significant difference from 5448, 
where P < 0.05. (f) Survival curves following subcutaneous infection of humanized 
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plasminogen transgenic mice (n = 10) with GAS strain 5448 (3.2 × 108 colony 
forming units/dose; solid line), 5448AP (1.6 × 108 colony forming units/dose; dashed 
line) and 5448APΔska (1.5 × 108 colony forming units/dose; dotted line). (g) 
Enumeration of bacterial counts in the site of infection, blood, spleen and liver of 
humanized plasminogen mice (n = 5) subcutaneously infected with GAS strain 5448 
(2.6 × 107 colony forming units/dose; open circles) and 5448AP (4.9 × 107 colony 
forming units/dose; filled circles). 
 
Fig. 2. Relative expression of (a) the speB gene and (b) the sda1 gene, as determined 
using quantitative real-time PCR (n = 3; mean ± SD). RNA was extracted from GAS 
either immediately prior to inoculation (0 h) or 24 h post-inoculation of subcutaneous 
infection chambers. Asterisk indicates statistically significant difference from 5448 (0 
h), where P < 0.05. (c) DNase expression in GAS mid-logarithmic phase culture 
supernatants as assessed by degradation of calf thymus DNA (control). (d) Clearance 
of NETs by GAS. Neutrophils were visualized using bright field microscopy, whilst 
NETs were visualized using Sytox Orange staining. Scale bar = 100 μm. (e) Killing of 
GAS by human neutrophils at a multiplicity of infection (GAS:neutrophils) = 1:10 (n 
= 3; mean ± SD). Asterisk indicates statistically significant difference from 5448, 
where P < 0.05. (f) The capacity of GAS strains 5448, 5448Δsda1, 5448RCsda1+, 
5448Δsmez and SF370 to phase-shift to a SpeB-negative phenotype was examined 3 d 
post-subcutaneous infection of mice. 
 
Fig. 3. Model for group A streptococcal invasive disease initiation and progression. 
(a) Following entry via the skin, GAS (blue) are able to express SpeB (required 
during the early stages of the infection process; black dots). An innate immune 
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response is mounted by host neutrophils and entrapment of GAS in NETS (orange) 
begins. (b) Within the GAS population, a mutation in covRS occurs (green), resulting 
in loss of SpeB expression and improved resistance to killing by neutrophils. (c) 
Selection pressure by neutrophils results in an increase in the proportion of covRS 
mutant phenotype GAS within the bacterial population, improved NET clearance and 
neutrophil resistance. (d) Loss of SpeB expression allows the accumulation of surface 
plasmin activity leading to systemic infection.  
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Supplementary Table 1. CovRS DNA sequence analysis of selected GAS 
M1T1 strain 5448 SpeB-negative derivatives isolated 3 d following 
subcutaneous infection of C57BL/J6 mice. 
 
GAS strain Mouse ID Tissuea Mutationb Consequencec 
5448-APD1 OS41B Blood C to T nt 838 covS H to Y aa 280 covS 
5448-APD2 OS41B Lesion C to T nt 838 covS H to Y aa 280 covS 
5448-APD3 OS41B Lesion C to T nt 838 covS H to Y aa 280 covS 
5448-APD4 OS45R Blood C to T nt 838 covS H to Y aa 280 covS 
5448-APD5 OS45R Blood C to T nt 838 covS H to Y aa 280 covS 
5448-APD6 OS46L Lesion Δ nt 83 covS Truncation in CovS 
5448-APD7 OS46L Lesion Δ nt 83 covS Truncation in CovS 
5448-APD8 OS46L Lesion G to A nt 331 covR A to T aa 111 covR 
5448-APD9 OS322B Lesion Δ nt 406-1503 covS Truncation in CovS 
5448-APD10 OS492L Lesion C to T nt 838 covS H to Y aa 280 covS 
aMouse tissue from which GAS strain was isolated 3 d post-subcutaneous 
infection. 
bMutation positions are based upon nucleotide (nt) position in the covR or 
covS genes, relative to each ATG start codon.  
cSubstitutions in CovR and CovS are based upon amino acid (aa) position in 
each open reading frame, relative to each start codon. 
 
Supplementary Table 2. Oligonucleotide primers used in this study for 
construction of recombinant GAS strains. 
 
Primer Direction bp Sequence 
RCSdapHY304Fwd Forward 29 GGGCTGCAGCTTAAACGTTGGTATTTTTA 
RCSdapHY304Rev Reverse 28 GGGGAATTCGGATAGCTTACAACTAGTG 
SdaF2 Forward 21 ATGTCTAAACATTGGAGACAT 
SdaR4 Reverse 20 ATCAGATGATAAAGCAGACA 
SmeZ-UpF Forward 20 TGGCTGACAACTGTCAGGAA 
SmeZ-UpR Reverse 54 GGTGGTATATCCAGTGATTTTTTTCTCCATAAATAGCCT
CTTTTCAGGAGTTAT 
SmeZ-DownF Forward 54 TACTGCGATGAGTGGCAGGGCGGGGCGTAATTCAATTT
TTCAATATAACTTTTA 
SmeZ-DownR Reverse 20 AACGACACCTCTTTCAGCGA 
Emm1-dis-F-BamHI Forward 30 GCGGATCCTAGTCCTGACTCGCTTGGTCTA 
Emm1-dis-R-XbaI Reverse 30 GCATCTAGACTTGCAGCAAACAATCCCGCA 
M1ska-dis-F-BamHI Forward 30 GCGGATCCAACATCACAACCTGCTCACGGA 
M1ska-dis-R-XbaI Reverse  GCGTCTAGACGCGCACATGTCCCTTTAACAA 
T7-For Forward 21 GTAATACGACTCACTATAGGG 
Emm1out-R Reverse 24 GAGGTTAAGGCTAACGGTGATGGT 
M1skaout-R Reverse 24 TTGAGCCCTGGTCTGAAATCGTCA 
 
Supplementary Table 3. Oligonucleotide primers used in this study for 
covRS PCR and sequence analysis. 
 
Primer Direction bp Sequence 
p1 Forward 19 GCTATTCCGGTACAGGTCT 
p2 Forward 19 GTCAATGGTCGTGAAGGGT 
p3 Forward 22 GATGTCTATATTCGTTATCTCC 
p4 Forward 22 GATGATTTTTACCACAGATAAC 
p5 Forward 20 GCATATTGGTCTCTTACAAC 
p6 Forward 21 GCAAATTGTAGATGGGTATCA 
p7 Reverse 20 GCGGAAAATAGCACGAATAC 
p8 Reverse 20 AGGCAATCAGTGTAAAGGCA 
p9 Reverse 21 CTTGTGCCAAATAACTCAACA 
p10 Reverse 21 ATCAAAAGCCTGCTCAAATGA 
p11 Reverse 21 CTTTCATGTCATCCATCATTG 
p12 Reverse 19 TTGCTCTCGTGTGCCATCT 
 
 
Supplementary Materials and Methods 
 
Culture of group A streptococci. S. pyogenes strains were routinely propagated at 37 
°C on horse blood agar (BioMérieux) or in static liquid cultures of Todd-Hewitt broth 
(Difco) supplemented with 1% (w/v) yeast extract (THBY). Invasive GAS isolate 
5448 (M1T1) and the isogenic animal-passaged SpeB-negative variant 5448AP have 
been described previously11. The isogenic mutants 5448Δsda15, 5448ΔspeB11 and 
GAS strain SF37019, have also been described previously.  
 
Construction of recombinant GAS strains. Allelic exchange was used to precisely 
replace the deleted sda1 chromosomal locus in 5448Δsda1 with the WT sda1 gene to 
construct strain 5448RCsda1+. The technology employed to construct 5448RCsda1+ 
was similar to that used in the construction of 5448Δsda15. The PCR primers 
RCSdapHY304Fwd and RCSdapHY304Rev were employed for amplification of 
flanking DNA upstream and downstream of sda1 in the 5448 chromosome 
(Supplementary Table 2). Following amplification, the sda1 gene was cloned by 
PstI/EcoRI digestion and T4 ligation into the temperature-sensitive plasmid pHY3045. 
The resulting plasmid (pHYsda1) was transformed into 5448∆sda1 by 
electroporation. Integration of pHYsda1 into the chromosome via single-crossover 
was achieved by culture at the permissive temperature for plasmid replication (30 ˚C).  
Following subculture at 37 ˚C, single-crossover chromosomal insertions were selected 
using chloramphenicol (∆sda1) and erythromycin (pHY304). Double-crossover was 
achieved by serial passage at 30 ˚C, and double-crossover reverse-complemented 
mutants were identified following removal of antibiotic selection. The reverse-
complemented strain 5448RCsda1+ was characterized as sensitive to both 
 
chloramphenicol and erythromycin; confirmed as sda1 PCR-positive using the 
forward primer SdaF2 and reverse primer SdaR4 (Supplementary Table 2); and able 
to express Sda1 upon assaying for DNase activity (as described below).  
 
The isogenic 5448Δsmez mutant was constructed in a manner identical to 5448Δsda1, 
as previously described5. A precise, in-frame allelic exchange replacement of the 
smeZ gene in GAS strain 5448 with a chloramphenicol acetyltransferase (cat) 
antibiotic resistance cassette was generated. The specific primer sets used for 
amplification of the flanking DNA upstream and downstream of smeZ in the 5448 
chromosome are given (Supplementary Table 2). The primers SmeZ-UpR and 
SmeZ-DownF contain a 25 bp 5’ extension corresponding to the 5’ and 3’ ends of the 
cat gene, respectively. 
 
Integrational mutagenesis of ska and emm1 was performed essentially as previously 
described20. Internal fragments of the genes ska and emm1 were PCR amplified from 
GAS strain 5448 using specific primer pairs (Supplementary Table 2) and cloned by 
BamHI/XbaI digestion and T4 ligation into the temperature-sensitive plasmid 
pVE600721. The resultant plasmids were transformed into 5448AP by electroporation 
and chloramphenicol resistant transformants were grown at the permissive 
temperature for plasmid replication (30 ˚C). Single-crossover Campbell-type 
chromosomal insertions were selected by shifting to the non-permissive temperature 
(37 ˚C), while maintaining chloramphenicol selection. Integrational knockouts were 
confirmed by PCR using the forward primer T7-For and reverse primer emm1out-R 
or M1skaout-R (Supplementary Table 2). Confirmed integrational knockouts were 
designated 5448APΔemm1 and 5448APΔska. 
 
 
Molecular and phenotypic analysis of GAS. To screen GAS strains for mutations in 
the covRS locus, we designed 12 primers for PCR and DNA sequence analysis 
(Supplementary Table 3 and Fig. 1a). Firstly, primers p1 and p12 were used to PCR 
amplify the intact covRS locus from genomic DNA which was extracted by phenol-
chloroform. Then, an ABI PRISM 7700 Sequence Detection System (Applied 
Biosystems) was used to directly sequence the amplified PCR product with the 12 
primers and the sequence assembled by the use of Sequencher version 4.5 (Gene 
Codes Corporation). Using BLASTN analysis, the assembled sequences were aligned 
against GAS genomes and a single adenine base insertion mutation was identified at 
position 877 in the 5448AP covS gene, using numbering relative to the ATG start 
codon of 5448 covS. Other in vivo-derived, SpeB-negative GAS strain 5448 
derivatives were analyzed for covRS mutations in an identical manner. 
 
SpeB-positive and SpeB-negative isolates were routinely identified by the Columbia 
skim milk agar assay22. Quantitative SpeB assays were undertaken as previously 
described23. Bacterial surface plasmin acquisition from human plasma assays and 
western blot identification of α-enolase, GAPDH, streptokinase and M1 protein, were 
conducted essentially as previously described4, with exception that cross-specific 
rabbit M53 protein-specific serum was used to identify M1 protein. GAS strain 
NS113324 was used as an internal control for bacterial surface plasmin acquisition 
assays4 undertaken by incubating bacteria overnight in human plasma. Plasminogen-
binding assays were conducted as previously described24. 
 
 
Virulence of GAS in a humanized plasminogen transgenic mouse model. 
Transgenic humanized plasminogen AlbPLG1 mice heterozygous for the human 
plasminogen transgene16 were backcrossed greater than n = 6 with C57BL/J6 mice 
(Animal Resources Centre, Perth, Australia). GAS strains 5448 and 5448AP were 
harvested at logarithmic phase (OD600 approx. 0.4), washed twice with sterile 0.7% 
saline and diluted to the required dose. The number of viable bacteria was determined 
by counting colony forming units (CFU) after plating a dilution series onto blood 
agar. The SpeB expression status of 5448 and 5448AP was also determined as 
described above (n = 50). The 5448AP inoculum was found to be 100% SpeB-
negative, while the 5448 inoculum was 100% SpeB-positive. Groups of AlbPLG1 
mice (n = 10) were subcutaneously infected with GAS and mortality was monitored 
for 10 d. Alternatively, groups of AlbPLG1 mice (n = 5) were subcutaneously infected 
with either 5448 or 5448AP for 48 h and the lesion (site of infection), blood, spleen 
and liver harvested. Lesion, spleen and liver samples were homogenized in 2 ml of 
sterile 0.7% saline. The number of viable bacteria was determined by counting CFU 
after plating a dilution series onto blood agar.  
 
Isolation of mRNA and real-time PCR analysis. In order to isolate in vivo-derived 
RNA, we utilized the subcutaneous Teflon chamber model25. Teflon chambers were 
inserted surgically under the skin of 6-week-old female BALB/c mice. Three weeks 
after surgery, tissue chamber fluid (TCF) was collected and tested for sterility. Mice 
that had contaminated TCF, or those that had open surgical wounds, were excluded 
from further experimentation. To prepare inocula, bacteria were grown overnight in 
THBY, checked for SpeB phenotype as detailed above, then subcultured for 18 h in 
THBY. Bacterial pellets were washed twice in sterile phosphate buffered saline (PBS) 
 
and resuspended in sterile PBS to 1 × 109 CFU/ml. We injected 100 μl of this 
bacterial suspension into the subcutaneous chambers using sterile 25-gauge needles. 
At 24 h post-injection, sterile 25-gauge needles were used to collect the TCF to 
analyze bacterial content and SpeB status, and to extract RNA from recovered 
bacteria11, 25. This 24 h time point was chosen as WT 5448 GAS recovered from 
mouse infection chambers were > 95% SpeB-positive (data not shown), whereas after 
3 d in vivo the WT subcutaneous bacterial population contain a significant proportion 
(up to 74%) of SpeB-negative phenotype4. 5448AP cells recovered from 24 h 
infection chambers were uniformly SpeB-negative. RNA was extracted from bacterial 
pellets using RNeasy kits (Qiagen), treated with DNase (Ambion) for 1 h to remove 
contaminating genomic DNA, and then recovered using RNeasy columns (Qiagen). 
The absence of genomic DNA in the RNA samples was confirmed by PCR using 
primers specific for the speB gene11 (data not shown). The intactness and purity of 
isolated RNA was assessed using an Agilent Technologies Bioanalyzer (data not 
shown). Superscript II (Invitrogen) was used to reverse transcribe RNA into cDNA, 
following the manufacturer’s protocol; cDNA was immediately diluted with four 
volumes of sterile water then aliquoted for real-time PCR reactions. We performed all 
Sybr-Green real-time quantitative PCR reactions using an ABI PRISM 7700 
Sequence Detection System (Applied Biosystems) and calculated relative expression 
amounts using the delta-delta CT method11. All real-time PCR reactions were 
performed using biological triplicates; product specificity was confirmed by the 
presence of a single peak in dissociation curves. Fluorescence in all real-time 
quantitative PCR reactions was measured at 75 ˚C, a temperature at which any 
potential primer dimers would melt, ensuring that the PCR product measured was the 
 
expected product. Primers used for real-time PCR analysis of speB and sda1 have 
been previously described11, 26. 
 
DNase activity assays. Supernatants were collected from mid-logarithmic (OD600 = 
0.4) or stationary phase cultures of GAS strains grown in THBY. Calf thymus DNA 
(1.0 μg/μl) was combined with bacterial supernatant (2.5 μl) in final volume of 50 μl 
buffer (300 mM Tris, 3 mM CaCl2, 3 mM MgCl2) for 15 min at room temperature. To 
halt DNase activity, 12.5 μl of 0.33 M EDTA was added to the reaction. Visualization 
of relative DNA degradation was undertaken by side-by-side comparison of DNA 
using 1% agarose gel electrophoresis. 
 
Live cell imaging for visualization of NETs. NETs were visualized as previously 
described5. Briefly, neutrophils were seeded at 2 × 105 per well in 96-well plates in 
RPMI without phenol red (Invitrogen). GAS were added to the wells at a multiplicity 
of infection of 1:100 (GAS:neutrophils) and Sytox Orange (Molecular Probes) added 
to a final concentration of 0.1 μM. Cells were visualized without fixation or washed 
using a Zeiss Axiovert 100 inverted microscope with appropriate fluorescent filters, 
and images captured with a CCD camera. For quantitation, NETs were enumerated 
for each treatment by counting three fields of view after staining from three 
independent wells; a NET was defined as a discrete area of bright orange fluorescence 
larger in size than a neutrophil. Presented data are representative of experiments 
undertaken on three separate occasions. 
 
Neutrophil killing assays. Neutrophil killing assays were performed as previously 
described5. Briefly, human neutrophils were isolated and purified from venous blood 
 
using the PolyMorphPrep kit (Axis-Shield) as per the manufacturer’s instructions and 
seeded into 96-well plates at 2 × 105 cells/well. Logarithmic-phase bacteria grown in 
THBY were diluted to the desired concentration in RPMI media containing 2% heat 
inactivated autologous human plasma, then added to neutrophils at a multiplicity of 
infection of 1:10 (GAS:neutrophils). Plates were centrifuged at 500 × g for 10 min 
then incubated at 37 °C in 5% CO2. Following incubation for 1 h, neutrophils were 
lysed with 0.02% Triton X-100 and the contents of the well serially diluted and plated 
on Todd-Hewitt agar for overnight incubation and enumeration of CFU. Internal 
control wells without neutrophils were used to determine baseline bacterial counts at 
the assay endpoints. Percent survival of GAS was calculated as ([CFU/ml 
experimental well] / [CFU/ml control well]) × 100%. All assays were performed in 
triplicate. 
 
Monitoring the in vivo phase-shift of GAS strains.  Separate cohorts of C57BL/J6 
mice (n = 10) were inoculated subcutaneously with a non-lethal dose of GAS to 
examine the in vivo phase-shift of SpeB during infection. The inocula used in these 
experiments were plated out onto blood agar plates then individual colonies tested for 
SpeB expression status as described above (n = 50). The 5448, 5448Δsda1, 
5448RCsda1+ and 5448Δsmez inocula were found to be 100% SpeB-positive. On day 
three post-infection, mice were sacrificed by CO2 asphyxiation and representative 
bacteria isolated from skin lesions4. The SpeB status of individual colonies (n = 50) 
was determined as described above.  
 
All animal experiments were conducted according to the Guidelines for the Care and 
Use of Laboratory Animals (National Health and Medical Research Council, 
 
Australia) and were approved by the University of Wollongong Animal Ethics 
Committee. 
 
Statistical analyses. Statistical analysis of SpeB expression and status, plasminogen-
binding, surface plasmin activity, quantitative real-time PCR, human neutrophil 
killing assays, and NET quantification were performed using a one way ANOVA with 
a Dunnett’s Multiple Comparison Test. Differences were considered statistically 
significant at P < 0.05. Differences in survival of humanized plasminogen transgenic 
mice infected with GAS strains 5448, 5448AP and 5448APΔska were determined by 
the log-rank test. All statistical tests were performed using GraphPad Prism version 
4.02.  
  
